(LOS ANGELES) – Cancerous tumors are made up of rapidly growing, abnormally shaped, cells that can infiltrate and destroy healthy tissues, travel to other parts of the body, and form additional tumors. In part because of its rapid and invasive nature, cancer remains the second leading cause of death in the United States and a major cause of death worldwide.
Tumor formation is often driven by genes called oncogenes, which are usually involved in the normal processes of cell growth, proliferation, and death. But they can also mutate and be expressed at high levels, which can drive the multiplication of cancerous cells.
Mutated oncogenes work in various ways, including on target cells’ chromatin, compact, dense structures of DNA and selected protein molecules. Oncogenes also work with an extensive variety of protein complexes that help turn specific genes “on” or “off” by binding to certain regions of the DNA.
The most well-known oncogene is Kras. Mutant Kras is found in 20% of all human cancers, including 97% of pancreatic ductal, 45% of colorectal, and 30% of lung cancers.
Despite the attention focused on mutant Kras tumor formation, the question remains as to why Kras mutation is so essential for oncogenesis. The conventional wisdom is that Kras mutation simply promotes cell proliferation. However, as many genes can promote cell proliferation, what makes Kras so deadly and difficult to treat?
A collaborative team that includes researchers from the Terasaki Institute for Biomedical Innovation (TIBI) and Duke University led by Dr. Xiling Shen, a professor and the chief scientific officer of TIBI, has been able to shed light on these processes. In a recent study, published in Developmental Cell, they discovered that Kras mutation causes rearrangements of chromatin inside cells. This rearrangement causes tissue cells to revert to an early developmental, or “stem-like” state and erroneously start to regenerate “new tissue,” causing the onset of tumor formation.
The team revealed that Kras-induced chromatin remodeling was mediated by a protein complex called AP-1, which binds and opens chromatins to rewire the cell’s fate. The AP-1 mediated chromatin accessibility mechanism seems to be a common process in tumor initiation, including in the lung, skin, and intestine. The team demonstrated that small-molecule drugs inhibiting AP-1 deterred oncogenesis and cell proliferation, providing a promising way to treat Kras-mutant tumors. This is especially significant because, currently, the majority of Kras tumors are not treatable with drugs.
What is even more fascinating is that Kras/AP-1 induced chromatin remodeling instills plasticity, or the ability to assume different cellular characteristics in response to mutations. Hence, Kras-mutant cells from different origins such as alveolar cells in the lungs and club cells in the airway will start masking their cell identity and become alike to one another. This sheds new light on the question of how lung cancer originates.
According to Dr. Shen, “Our study demonstrates the ability of Kras to use genetic reprogramming to make cells more stem-like and plastic; it resolves the long-standing debate over why Kras is so special in tumor formation. Our elucidation of the AP-1 complex as its effector for chromatin remodeling opens new therapeutic opportunities to target Kras, a notoriously hard-to-drug target.”
“An understanding of the complex processes involved in tumorigenesis is essential for designing drug treatments and screening platforms for cancer,” said TIBI Director and CEO, Ali Khademhosseini, PhD. “Dr. Shen’s work will prove invaluable in meeting those needs and will dovetail with the drug delivery and physiological models platforms that we have here at the institute.”
Authors are Preetish Kadur Lakshminarasimha Murthy, Rui Xi, Diana Arguijo, Jeffrey I. Everitt, Dewran D. Kocak, Yoshihiko Kobayashi, Aline Bozec, Silvestre Vicent, Shengli Ding, Gregory E. Crawford, David Hsu, Purushothama Rao Tata, Timothy Reddy, and Xiling Shen.
This work was funded by NIH U01 CA217514, U01 CA214300, and R35 GM122465 to XS and DFG-SPP microbone (BO3811-1/7) grant to AB.
Stewart Han, email@example.com, +1 818-836-4393
Terasaki Institute for Biomedical Innovation
The Terasaki Institute for Biomedical Innovation (terasaki.org) is a non-profit research organization that invents and fosters practical solutions that restore or enhance the health of individuals. Research at the Terasaki Institute leverages scientific advancements that enable an understanding of what makes each person unique, from the macroscale of human tissues down to the microscale of genes, to create technological solutions for some of the most pressing medical problems of our time. We use innovative technology platforms to study human disease on the level of individual patients by incorporating advanced computational and tissue-engineering methods. Findings yielded by these studies are translated by our research teams into tailored diagnostic and therapeutic approaches encompassing personalized materials, cells and implants with unique potential and broad applicability to a variety of diseases, disorders, and injuries.
The Institute is made possible through an endowment from the late Dr. Paul I Terasaki, a pioneer in the field of organ transplant technology.
Method of Research
Subject of Research
Epigenetic basis of oncogenic-Kras mediated epithelial-cellular proliferation and plasticity
Article Publication Date